
IGC Stock Forecast & Price Target
IGC Analyst Ratings
Bulls say
IGC Pharma is supported by a compelling Alzheimer’s pipeline, led by IGC-AD1, which has shown promise in cell lines against plaques and tangles and produced clinically and statistically significant agitation reduction versus placebo in a March 2024 interim analysis. The investment case is strengthened by execution progress, with 100% enrollment of the 146-patient Phase 2 CALMA trial achieved in August and the company now within 6 additional randomizations of closure, while earlier April updates showed over 80% enrollment. With two major milestones expected in 2026, an attractive NPV-based valuation, and a billion-dollar market opportunity, the stock offers substantial upside if positive data continue to validate the program.
Bears say
IGC Pharma is an early/clinical-stage biotech with minimal revenue, posting just $0.3 million in both fiscal Q1 2026 and fiscal Q2 2026, while losses widened to $2.4 million and $2.9 million, respectively, underscoring a persistently weak earnings profile. Its Alzheimer’s pipeline may address a large unmet need, but the company remains dependent on unproven product candidates such as IGC-AD1, IGC-M3, IGC-1C, and TGR-63 to demonstrate safety, efficacy, and regulatory viability before any meaningful commercialization can occur. Balance sheet and liquidity risk, reimbursement uncertainty, and competitive and macroeconomic pressures further limit conviction, especially given the limited and transient effects of currently available Alzheimer’s drugs.
This aggregate rating is based on analysts' research of India Globalization Capital and is not a guaranteed prediction by Public.com or investment advice.
IGC Analyst Forecast & Price Prediction
Start investing in IGC
Order type
Buy in
Order amount
Est. shares
0 shares